EUCTR2011-005145-12-GR进行中（未招募）不适用
A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED CLINICAL TRIAL OF THE SAFETY AND EFFICACY OF ANAKINRA IN PATIENTS WITH HIDRADENITIS SUPPURATIVA (PROTOCOL: HIDRA03) - ANAKINRA IN HIDRADENITIS SUPPURATIVA
niversity of Athens, Medical School0 个研究点开始时间: 2011年11月21日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •written informed consent provided by the patient;
- •age above 18 years;
- •diagnosis of HS; and
- •HS of Hurley II or III stage disease
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 18
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •history of systemic lupus erythematosus, of rheumatoid arthritis of of seronegative inflammatory arthritis;
- •any prior administration of any type of anti-TNF therapy over the last six months;
- •administration of any live (attenuated) vaccine over the last 4 weeks;
- •history of recurrent vein thrombosis or embolism compatible with anti-cardiolipin syndrome;
- •any present or smoldering infection;
- •hepatic dysfunction defined as any value of transaminases, of ?-glutamyl transpeptidase or of bilirubin> 2 x upper normal limit;
- •history of haematological or solid tumor malignancy, arterial hypertension, liver cirrhosis, HIV infection, and hepatitis virus B or C infection
- •history of episodes mimicking demyelinating disorders or a definite diagnosis of multiple sclerosis
- •any creatinine value above 1.5 mg/dl
- •intake of corticosteroids defined as daily intake of prednisone or equivalent more than 1mg/kg for the last three weeks;
- •neutropenia defined as <1000 neutrophils/mm3; and
- •pregnancy or lactation
研究者
相似试验
进行中（未招募）
1 期
A NEW ANTIBODY FOR HIDRADENITIS SUPPURATIVAEUCTR2015-002321-20-GRHellenic Institute for the Study of Sepsis
进行中（未招募）
1 期
BENEFIT OF CLARITHROMYCIN IN PATIENTS WITH SEVERE INFECTIONS THROUGH MODULATION OF THE IMMUNE SYSTEMIMMUNE MODULATION WITH CLARITHROMYCIN IN SEPSIS WITH MULTIPLE ORGAN AND RESPIRATORY DYSFUNCTIONMedDRA version: 20.0Level: PTClassification code 10040047Term: SepsisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2017-001056-55-GRHELLENIC INSTITUTE FOR THE STUDY OF SEPSIS110
进行中（未招募）
1 期
BENEFIT OF CLARITHROMYCIN IN PATIENTS WITH SEVERE INFECTIONS THROUGH MODULATION OF THE IMMUNE SYSTEMIMMUNE MODULATION WITH CLARITHROMYCIN IN SEPSIS WITH MULTIPLE ORGAN AND RESPIRATORY DYSFUNCTIONMedDRA version: 20.0 Level: PT Classification code 10040047 Term: Sepsis System Organ Class: 10021881 - Infections and infestationsEUCTR2017-001056-55-BEHELLENIC INSTITUTE FOR THE STUDY OF SEPSIS110
未知
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRAIL TO COMPARE THE SAFETY AND EFFICACY OF REDUCED DOSE EFAVIRENZ (EFV) WITH STANDARD DOSE EFV PLUS TWO NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS (N(T)RTI) IN ANTIRETROVIRAL -NAIVE HIV-INFECTED INDIVIDUAL OVER 96 WEEKSPER-094-11The Kirby Institute for infection and inmmunity in Society,
已完成
不适用
A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE, PHASE III STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF TICAGRELOR AND ASA COMPARED WITH ASA IN THE PREVENTION OF STROKE AND DEATH IN PATIENTS WITH ACUTE ISCHAEMIC STROKE OR TRANSIENT ISCHAEMIC ATTACK-I63-I67I63I67PER-036-17AstraZeneca AB,301